News
RNXT
1.370
-0.72%
-0.010
Weekly Report: what happened at RNXT last week (1230-0103)?
Weekly Report · 1d ago
Weekly Report: what happened at RNXT last week (1223-1227)?
Weekly Report · 12/30/2024 11:04
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
Barchart · 12/30/2024 07:00
Weekly Report: what happened at RNXT last week (1216-1220)?
Weekly Report · 12/23/2024 11:11
Weekly Report: what happened at RNXT last week (1209-1213)?
Weekly Report · 12/16/2024 11:12
RenovoRx announces SCRI Oncology partners enrolling patients for trial
TipRanks · 12/11/2024 13:12
RENOVORX INITIATES PATIENT ENROLLMENT AT SCRI ONCOLOGY PARTNERS FOR ONGOING PIVOTAL PHASE III TIGER-PAC CLINICAL TRIAL IN LOCALLY ADVANCED PANCREATIC CANCER
Reuters · 12/11/2024 13:00
RenovoRx Price Target Raised to $9.00/Share From $8.25 by Ascendiant Capital
Dow Jones · 12/10/2024 09:31
RenovoRx Is Maintained at Buy by Ascendiant Capital
Dow Jones · 12/10/2024 09:31
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $9
Benzinga · 12/10/2024 09:21
Weekly Report: what happened at RNXT last week (1202-1206)?
Weekly Report · 12/09/2024 11:10
RenovoRx Secures Initial Purchase Orders for RenovoCath as Nationwide Demand Grows
Barchart · 12/05/2024 17:20
RenovoRx receives first purchase orders for FDA-cleared RenovoCath
TipRanks · 12/05/2024 13:06
RENOVORX RECEIVES FIRST PURCHASE ORDERS FOR ITS FDA-CLEARED RENOVOCATH® DELIVERY SYSTEM
Reuters · 12/05/2024 13:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 12/02/2024 21:05
Weekly Report: what happened at RNXT last week (1125-1129)?
Weekly Report · 12/02/2024 11:11
Weekly Report: what happened at RNXT last week (1118-1122)?
Weekly Report · 11/25/2024 11:03
RenovoRx Expands TIGeR-PaC Study with Northwell Health Cancer Institute to Evaluate Innovative Treatment for Locally Advanced Pancreatic Cancer
Barchart · 11/20/2024 17:52
RenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial
TipRanks · 11/20/2024 13:50
RenovoRx Announces That The Northwell Health Cancer Institute In New Hyde Park, NY Is Enrolling Patients With Locally Advanced Pancreatic Cancer In The Co's Ongoing Phase III TiGeR-PaC Clinical Trial; NHCI Joins Esteemed Clinical Sites Throughout The U.S. Participating In The Study
Benzinga · 11/20/2024 13:47
More
Webull provides a variety of real-time RNXT stock news. You can receive the latest news about Renovorx Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNXT
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.